Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Schattenberg
L Stump

Showing results (21-30 of 464) with videos related to

Pageof 47
Sort By:
Zeitschrift Fur Gastroenterologie|July 8, 2024
Jörn M Schattenberg, Frank Tacke
Alimentary Pharmacology & Therapeutics|February 10, 2021
Letter: proton pump inhibitor use and bone fracture risk-a mechanistic point of view. Authors' replyChristian Labenz, Jörn M Schattenberg
Zeitschrift Fur Gastroenterologie|December 6, 2016
[Prime time for medical therapy in NASH?]Christian Labenz, Jörn M Schattenberg
JHEP Reports : Innovation in Hepatology|August 14, 2025
Targeting fibrosis and steatohepatitis through the metabolism - results from the ESSENCE trialMaurice Michel, Jörn M Schattenberg
Nutrients|March 14, 2019
Nutritional Intake and the Risk for Non-Alcoholic Fatty Liver Disease (NAFLD)Jörn M Schattenberg, Ina Bergheim
Handbook of Experimental Pharmacology|November 23, 2021
NAFLD and NASH: The Metabolically Diseased LiverAngelo Armandi, Jörn M Schattenberg
Zeitschrift Fur Gastroenterologie|December 8, 2020
[Liver-specific diagnostic for non-alcoholic fatty liver disease (NAFLD) - time to replace liver biopsy?]Maurice Michel, Jörn M Schattenberg
Hepatology (Baltimore, Md.)|December 6, 2018
Refining Noninvasive Diagnostics In Nonalcoholic Fatty Liver Disease: Closing the Gap to Detect Advanced FibrosisJörn M Schattenberg, Rohit Loomba
Gastroenterology|February 19, 2020
Metabolic Inflammation-A Role for Hepatic Inflammatory Pathways as Drivers of Comorbidities in Nonalcoholic Fatty Liver Disease?Nadine Gehrke, Jörn M Schattenberg
European Journal of Heart Failure|April 15, 2026
The spectrum of steatotic liver disease (SLD) in cardiology - time to screen for coexisting liver diseaseAnnalisa Cespiati, Jörn M Schattenberg
Pageof 47

Showing results (21-30 of 464) with videos related to

Sort By:
Pageof 47
Zeitschrift Fur Gastroenterologie|July 8, 2024
Jörn M Schattenberg, Frank Tacke
Alimentary Pharmacology & Therapeutics|February 10, 2021
Letter: proton pump inhibitor use and bone fracture risk-a mechanistic point of view. Authors' replyChristian Labenz, Jörn M Schattenberg
Zeitschrift Fur Gastroenterologie|December 6, 2016
[Prime time for medical therapy in NASH?]Christian Labenz, Jörn M Schattenberg
JHEP Reports : Innovation in Hepatology|August 14, 2025
Targeting fibrosis and steatohepatitis through the metabolism - results from the ESSENCE trialMaurice Michel, Jörn M Schattenberg
Nutrients|March 14, 2019
Nutritional Intake and the Risk for Non-Alcoholic Fatty Liver Disease (NAFLD)Jörn M Schattenberg, Ina Bergheim
Handbook of Experimental Pharmacology|November 23, 2021
NAFLD and NASH: The Metabolically Diseased LiverAngelo Armandi, Jörn M Schattenberg
Zeitschrift Fur Gastroenterologie|December 8, 2020
[Liver-specific diagnostic for non-alcoholic fatty liver disease (NAFLD) - time to replace liver biopsy?]Maurice Michel, Jörn M Schattenberg
Hepatology (Baltimore, Md.)|December 6, 2018
Refining Noninvasive Diagnostics In Nonalcoholic Fatty Liver Disease: Closing the Gap to Detect Advanced FibrosisJörn M Schattenberg, Rohit Loomba
Gastroenterology|February 19, 2020
Metabolic Inflammation-A Role for Hepatic Inflammatory Pathways as Drivers of Comorbidities in Nonalcoholic Fatty Liver Disease?Nadine Gehrke, Jörn M Schattenberg
European Journal of Heart Failure|April 15, 2026
The spectrum of steatotic liver disease (SLD) in cardiology - time to screen for coexisting liver diseaseAnnalisa Cespiati, Jörn M Schattenberg
Pageof 47